|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||219.58 - 224.23|
|52 Week Range||151.80 - 225.66|
|Beta (3Y Monthly)||1.49|
|PE Ratio (TTM)||26.70|
|Earnings Date||Feb 3, 2020 - Feb 7, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||232.27|
Vertex's (VRTX) Kalydeco gains EU nod for use in infants with cystic fibrosis aged from six to less than 12 months with at least one of specified nine mutations in the CFTR gene.
On Dec 9, the fear gauge jumped 16% as uncertainties in the closure of U.S.-China trade deal instilled fear in investors. Here are five defensive stocks to shield your portfolio.
Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label extension for KALYDECO® (ivacaftor) to include the treatment of infants with cystic fibrosis (CF) ages 6 months to less than 12 months weighing 5 kg and more who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.
Blueprint Medicines (BPMC) posts favorable initial data from the part 1 of phase II PIONEER study on avapritinib for the treatment of patients with indolent systemic mastocytosis. Stock rises.
Gilead (GILD) announces positive long-term data from a mid-stage study on Yescarta in adult patients with refractory large B-cell lymphoma.
Spero (SPRO) reports preliminary findings from a phase I first-in-human study on SPR720, presently being evaluated for the treatment of nontuberculous mycobacterial pulmonary disease.
Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.
Biogen (BIIB) posts favorable top-line results from a phase II study evaluating BIIB059 for treating cutaneous and systemic lupus erythematosus. The study tastes success by achieving its main goal.
Seattle Genetics (SGEN) and Astellas team up with Merck for a late-stage study to evaluate the enfortumab vedotin and Keytruda combo in patients with previously untreated metastatic urothelial cancer.
Puma Biotech (PBYI) stretches its license deal with Pierre Fabre, granting the latter commercial rights to Nerlynx in new countries across Europe and parts of Africa. Stock rallies.
Acorda's (ACOR) lead MS drug Ampyra is hit by generic competition in the United States, which is hurting the company's top line of late. Parkinson's disease drug Inbrija seems an ideal replacement.
Check out the latest fundings for Austin companies, including a deal that could be worth more than $500 million for a biotech firm. There's also another seltzer maker in town, spurred on by the founder of Big Ass Fans.
The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
The FDA accepts and grants priority review to Incyte's (INCY) new drug application for pemigatinib as a second-line treatment for patients with FGFR2 translocated cholangiocarcinoma.